Relay Therapeutics (NASDAQ: RLAY) net income
Relay Therapeutics reported a net loss of $276.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $337.7m. Earnings per share were −$1.61.
Relay Therapeutics's best year of the last 7 was fiscal 2020. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$276.5m | — | −1,800.6% | −$1.61 |
| 2024 | −$337.7m | — | −3,374.7% | −$2.36 |
| 2023 | −$342.0m | — | −1,338.7% | −$2.79 |
| 2022 | −$290.5m | — | −21,036.1% | −$2.59 |
| 2021 | −$363.9m | — | −12,012.9% | −$3.82 |
| 2020 | −$52.4m | — | −63.4% | −$5.40 |
| 2019 | −$75.3m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Relay Therapeutics net income compared with its sector
By net income for its latest fiscal year, Relay Therapeutics ranks 441st of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Relay Therapeutics, −1,800.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 439th | Ocular Therapeutix | −$265.9m | −511.9% |
| 440th | Lyell Immunopharma | −$274.4m | −762,355.6% |
| 441st | Relay Therapeutics | −$276.5m | −1,800.6% |
| 442nd | Kura Oncology | −$278.7m | −412.9% |
| 443rd | Claritev | −$284.3m | −29.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Relay Therapeutics
- How much did Relay Therapeutics earn in fiscal 2025?
- Relay Therapeutics reported a net loss of $276.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $337.7m.
- What are the earnings per share of Relay Therapeutics?
- They were −$1.61 in fiscal 2025, compared with −$2.36 in fiscal 2024.
- Where does Relay Therapeutics rank in its sector by net income?
- It ranks 441st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Relay Therapeutics come from?
- From the annual report (Form 10-K) that Relay Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Relay Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Relay Therapeutics: the Relay Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.